Bull
$10.16
Scenario price
$12.170
-0.192 (-1.58%)At close
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.
AngioDynamics Inc is a good buy right now due to its current price of $12.365, which is significantly below the analyst price targets of $19 to $20. The stock has shown a positive momentum with a 5-day change of +10.01%, and the RSI is at 57.536, suggesting it is neither overbought nor oversold. However, the main risk is the projected losses of $0.24 to $0.29 per share for fiscal 2027, indicating ongoing financial challenges.
Canaccord
$20
2026-07-15
Canaccord
2026-07-15
Price Target
$20
H.C. Wainwright
$19
2026-07-15
H.C. Wainwright
2026-07-15
Price Target
$19
Freedom Broker
$16
2026-04-06
Freedom Broker
2026-04-06
Price Target
$16
Canaccord
$16
2026-04-06
Canaccord
2026-04-06
Price Target
$16
Canaccord
$17
2025-07-16
Canaccord
2025-07-16
Price Target
$17
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

IRE Treatment Strategy Improves Survival in Stage III Pancreatic Cancer

Humana Updates Coverage Policy for NanoKnife IRE Treatment

AngioDynamics Q1 Earnings Beat Expectations but Stock Plummets

AngioDynamics Reports Continued Growth in Med Tech Segment

AngioDynamics Funds Study to Enhance PE Treatment Insights
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
AngioDynamics Inc is a good buy right now due to its current price of $12.365, which is significantly below the analyst price targets of $19 to $20. The stock has shown a positive momentum with a 5-day change of +10.01%, and the RSI is at 57.536, suggesting it is neither overbought nor oversold. However, the main risk is the projected losses of $0.24 to $0.29 per share for fiscal 2027, indicating ongoing financial challenges.
5 analysts cover ANGO: 1 rate it Buy, 4 Hold and 0 Sell. The average price target is 19.33.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.